Remora Biotech
Jean-Marc Le Doussal is an accomplished entrepreneur and biotech leader with extensive experience in the development of advanced therapeutics. As the Founder and CEO of Remora Biotech since January 2011, Jean-Marc has built a portfolio of companies focused on immunology and biotherapeutics. Currently serving as Founder and Chairman at Cellula Therapeutics, Jean-Marc is dedicated to developing next-generation CAR-T therapies for brain cancer. Additionally, Jean-Marc is the Founder and Chairman of OGD2 Pharma, specializing in anticancer immunotherapies, and Activen SA, which innovates miniproteins for the dermo-cosmetic industry. With past leadership roles including Founder and Chairman at Fastox Pharma and ATLAB Pharma, as well as a background in consultancy and research, Jean-Marc combines expertise in immunology and entrepreneurial acumen. Jean-Marc holds a Master's degree in Engineering from École Polytechnique, a PhD in Immunology from Aix-Marseille University, and two Executive MBAs from EPFL, emphasizing management, entrepreneurship, and innovation.
This person is not in any teams
Remora Biotech
Immunotherapy has an immense and growing impact on medicine and society : vaccines against pandemics, monoclonal antibodies – the most successful class of drugs, breakthrough cures of cancer and autoimmune diseases, and new hopes to fight degenerative diseases. As immunologists and serial entrepreneurs, we contributed, at our small individual scale, to this biopharmaceutical revolution driven by immunology. We now join forces at Remora Biotech to leverage our entrepreneurial experience and, thanks to our supporting investors, to scale-up our ability to nurture and develop innovative life-changing immunotherapies. With our growing team and network of academic partners, business-oriented scientists, patent experts, drug developers and finance professionals, we create, finance, and manage a portfolio of daughter companies from discovery to clinical proof-of-concept. We aim at maximizing their odds of success and their strategic value for pharma partners while keeping capital efficient. Investors keen to gain exposure to this high-growth and high-impact sector, under the leadership of seasoned entrepreneurs, may become a shareholder of Remora Biotech and co-invest in our daughter companies.